Navigation Links
Regeneron Submits Biologics License Application to FDA for VEGF Trap-Eye for Treatment of Wet Age-Related Macular Degeneration
Date:2/22/2011

eron's product and drug candidates, uncertainty of market acceptance of Regeneron's product and drug candidates, unanticipated expenses, the availability and cost of capital, the costs of developing, producing, and selling products, the potential for any license or collaboration agreement, including Regeneron's agreements with the sanofi-aventis Group and Bayer HealthCare, to be canceled or terminated without any product success, and risks associated with third party intellectual property.  A more complete description of these and other material risks can be found in Regeneron's filings with the United States Securities and Exchange Commission (SEC), including its Form 10-K for the year ended December 31, 2010. Regeneron does not undertake any obligation to update publicly any forward-looking statement, whether as a result of new information, future events, or otherwise, unless required by law.

Investor Relations Contact:Michael Aberman, M.D. Tel. +1 (914) 345-7799E-Mail: michael.aberman@regeneron.com Media Contact:Peter Dworkin, Tel. +1 (914) 345-7640E-Mail: peter.dworkin@regeneron.com
'/>"/>

SOURCE Regeneron Pharmaceuticals, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7

Related medicine technology :

1. Bayer and Regeneron Dose First Patient in Second Phase 3 Study for VEGF Trap-Eye in Wet Age-Related Macular Degeneration
2. Bayer and Regeneron Extend Development Program for VEGF Trap-Eye to Include Central Retinal Vein Occlusion
3. Enrollment Completed in Regeneron and Bayer HealthCare Phase 3 Studies of VEGF Trap-Eye in Neovascular Age-Related Macular Degeneration (Wet AMD)
4. Regeneron Announces Presentation at the 18th Annual Credit Suisse Healthcare Conference
5. Regeneron Reports Third Quarter 2009 Financial and Operating Results
6. Sanofi-aventis and Regeneron Expand Strategic Antibody Collaboration
7. Regeneron Announces Presentation at the Deutsche Bank 2009 Biotech Boston Confab
8. BioMed Realty Trust Signs New Lease With Regeneron Pharmaceuticals for 131,000 Square Feet at Landmark
9. Regeneron Announces Presentation at the Morgan Stanley Global Healthcare Conference
10. Regeneron Announces Presentation at the UBS Global Life Sciences Conference
11. Regeneron Announces Panel Discussion at Citis 5th Annual Biotech Day
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/22/2014)... , Oct. 22, 2014  AcelRx Pharmaceuticals, ... that results from the  IAP310 study have been ... (RAPM), a peer-reviewed journal with broad, multidisciplinary ... trial evaluating the safety and efficacy of Zalviso, ... system (SSTS), for the treatment of post-operative pain ...
(Date:10/22/2014)... JOLLA, Calif. , Oct. 22, 2014 ... RGLS ), a biopharmaceutical company leading the ... microRNAs, today announced that it has demonstrated ... an ongoing clinical study evaluating RG-101, a ... the treatment of hepatitis C virus infection ...
(Date:10/20/2014)... , Oct. 20, 2014  PneumRx, Inc. ( www.pneumrx.com ... today announced completion of enrollment in their RENEW Study, ... Study is the FDA-approved IDE pivotal trial for the ... It was anticipated that the study, which ... would take until the end of 2014 to enroll ...
Breaking Medicine Technology:AcelRx Announces Publication of Zalviso Phase 3 Abdominal Trial Results 2A Single Subcutaneous Dose of 2mg/kg of RG-101, Regulus' Wholly-Owned, GalNac-Conjugated anti-miR Targeting microRNA-122, Demonstrates 4.1 log10 Mean Viral Load Reduction as Monotherapy at Day 29 in Patients with Varied HCV Genotypes and Treatment H 2A Single Subcutaneous Dose of 2mg/kg of RG-101, Regulus' Wholly-Owned, GalNac-Conjugated anti-miR Targeting microRNA-122, Demonstrates 4.1 log10 Mean Viral Load Reduction as Monotherapy at Day 29 in Patients with Varied HCV Genotypes and Treatment H 3A Single Subcutaneous Dose of 2mg/kg of RG-101, Regulus' Wholly-Owned, GalNac-Conjugated anti-miR Targeting microRNA-122, Demonstrates 4.1 log10 Mean Viral Load Reduction as Monotherapy at Day 29 in Patients with Varied HCV Genotypes and Treatment H 4A Single Subcutaneous Dose of 2mg/kg of RG-101, Regulus' Wholly-Owned, GalNac-Conjugated anti-miR Targeting microRNA-122, Demonstrates 4.1 log10 Mean Viral Load Reduction as Monotherapy at Day 29 in Patients with Varied HCV Genotypes and Treatment H 5A Single Subcutaneous Dose of 2mg/kg of RG-101, Regulus' Wholly-Owned, GalNac-Conjugated anti-miR Targeting microRNA-122, Demonstrates 4.1 log10 Mean Viral Load Reduction as Monotherapy at Day 29 in Patients with Varied HCV Genotypes and Treatment H 6A Single Subcutaneous Dose of 2mg/kg of RG-101, Regulus' Wholly-Owned, GalNac-Conjugated anti-miR Targeting microRNA-122, Demonstrates 4.1 log10 Mean Viral Load Reduction as Monotherapy at Day 29 in Patients with Varied HCV Genotypes and Treatment H 7A Single Subcutaneous Dose of 2mg/kg of RG-101, Regulus' Wholly-Owned, GalNac-Conjugated anti-miR Targeting microRNA-122, Demonstrates 4.1 log10 Mean Viral Load Reduction as Monotherapy at Day 29 in Patients with Varied HCV Genotypes and Treatment H 8PneumRx Completes RENEW Pivotal Trial Enrollment 2PneumRx Completes RENEW Pivotal Trial Enrollment 3
... 12 Lexicon,Pharmaceuticals, Inc. (Nasdaq: LXRX ) ... drug (IND) application to the U.S. Food and ... for rheumatoid,arthritis and other autoimmune conditions. The initial ... a double-blind, randomized,placebo-controlled, ascending single-dose study in healthy ...
... Medical Lasers Limited,(ASX: ELX), a global leader in ... systems, announced today initial clinical results of,an ongoing ... demonstrate the therapy,s potential to improve and,stabilize visual ... with,diabetic maculopathy and macular edema without causing any ...
Cached Medicine Technology:Lexicon Files Investigational New Drug Application for LX2931 as a Potential Treatment for Rheumatoid Arthritis 2Lexicon Files Investigational New Drug Application for LX2931 as a Potential Treatment for Rheumatoid Arthritis 3Ellex 2RT Study Demonstrates Clinical Efficacy in Treatment of Diabetic Macular Edema 2Ellex 2RT Study Demonstrates Clinical Efficacy in Treatment of Diabetic Macular Edema 3Ellex 2RT Study Demonstrates Clinical Efficacy in Treatment of Diabetic Macular Edema 4
(Date:10/22/2014)... HealthDay Reporter , TUESDAY, Oct. 21, ... Ebola cases in Dallas. But, mental health specialists say overblown ... President Barack Obama on Friday appointed an Ebola "czar" to ... two Dallas nurses who cared for a Liberian man who ... But the U.S. cases are miniscule in the context ...
(Date:10/22/2014)... 2014 With the Affordable Care Act (ACA) ... the American Institutes for Research (AIR) finds that three out ... health insurance, but 42 percent say they are not likely ... signing up for coverage. , The AIR survey found wide ... able to calculate correctly how much they owe for a ...
(Date:10/22/2014)... Although there are only 24 hours in a day, that ... trouble finding time within their busy schedules for exercise and fitness. ... time to get in shape. Here are five ways you can ... , Change Up Your Commute , Consider riding a bike or ... into your daily routine. If you must use your car to ...
(Date:10/22/2014)... By Maureen Salamon ... -- Black women undergoing in vitro fertilization (IVF) are only ... using the popular assisted reproduction technique, new research indicates, and ... In the study, about 31 percent of white patients ... black patients. Analyzing more than 4,000 IVF cycles over ...
(Date:10/22/2014)... Thompson HealthDay Reporter , MONDAY, ... Monday officially tightened guidelines for health workers treating Ebola patients, ... use of a respirator at all times. The U.S. ... tougher rules after two Dallas nurses contracted Ebola while caring ... Liberian national Thomas Eric Duncan. Nina Pham is currently being ...
Breaking Medicine News(10 mins):Health News:Ebola Anxiety: A Bigger Threat Now Than the Virus Itself 2Health News:Ebola Anxiety: A Bigger Threat Now Than the Virus Itself 3Health News:Many Americans Fail to Ask Basic Questions Before Signing Up for Health Insurance, National Survey Finds 2Health News:Many Americans Fail to Ask Basic Questions Before Signing Up for Health Insurance, National Survey Finds 3Health News:Many Americans Fail to Ask Basic Questions Before Signing Up for Health Insurance, National Survey Finds 4Health News:HealthGuideMD Presents Ways to Improve Your Exercise and Fitness 2Health News:Black Women Fare Worse With Fertility Treatments, Study Says 2Health News:Black Women Fare Worse With Fertility Treatments, Study Says 3Health News:CDC Tightens Rules on Caring for Ebola Patients 2Health News:CDC Tightens Rules on Caring for Ebola Patients 3
... Club gathered in a central Taipei square Sunday to share ... ,Led by founder Chen Dar-cheng, the club members and their ... laughs with names like lion laugh, milkshake laugh and inner ... one club member, wearing a doctor's white gown and holding ...
... blur of fact and fiction which scientists say could confuse the ... made-for-television movie, airs May 9, just as scientists are to begin ... of bird flu in North America. Scientists fear the bird flu ... human, sparking a global pandemic. ,The two-hour movie brings ...
... After graduation students have to apply for a separate insurance ... parents insurance scheme//. But some may feel that they can ... disastrous if they are injured or diagnosed with a serious ... can be without insurance for a few months since there's ...
... taken a huge financial toll on the poultry sector, with ... and retail sale of chicken have drastically plummeted. ,Sindh ... recorded a loss of around Rs 60 million. Nearly 200,000 ... outbreak. , ,Following the outbreak, an effective monitoring system ...
... The American Heart Association/American Stroke Association has released a ... //These new guidelines are published in the rapid access ... ,Stroke is the third leading cause of death ... States. Every year about 700,000 people in the United ...
... flu shots in Ontario, flu vaccination rates have doubled ... ,Although bird flu vaccination rates have rose in ... all others. This is true even when factors such ... consideration. Ontario deserves credit implementing for universal flu shot ...
Cached Medicine News:Health News:Taiwanese Had A Hearty Laugh On World Laughter Day 2Health News:Bird Flu: Fact or Fiction 2Health News:Bird Flu: Fact or Fiction 3Health News:Insurance Plans after Graduation 2Health News:How To Prevent A Stroke 2Health News:How To Prevent A Stroke 3Health News:How To Prevent A Stroke 4Health News:Ontario Ranks Highest in Free Bird Flu Vaccination Rates 2
... RiOs systems produce Type III, laboratory-grade pure ... are fed directly with potable tap water ... compact system design that is easy to ... the water produced at a low operating ...
... 10,400 more samples than traditionally-insulated freezers, ... panel technology maximizes storage capacity. Freezer ... compartments; two adjustable-height shelves included. Patented ... energy consumption and extends compressor life. ...
... The NU-5510 DHD AutoFlow Direct ... HEPA filtration guarantying the greatest control ... cycles, both at 95C wet decontamination ... are exceptionally useful for cell line ...
... Simple, economical, moderate-sized CO2 incubator with ... with glass inner door, HEPA filtered ... minimize sample exposure. Simple, large character ... IR CO2 sensing and mulitple temperature ...
Medicine Products: